The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Psychopathological and Cognitive Effects of Therapeutic Cannabinoids in Multiple Sclerosis: A Double-Blind, Placebo Controlled, Crossover Study
Abstract
OBJECTIVES: To study possible psychopathological symptoms and cognitive deficits, abuse induction, as well as general tolerability and effects on quality of life, fatigue and motor function in cannabis-naïve patients with multiple sclerosis (MS) treated with a free-dose cannabis plant extract (Sativex). METHODS: In an 8-week, randomized, double-blind, placebo-controlled, parallel group crossover trial, 17 cannabis-naïve patients with MS were assessed at baseline and at the end of the cannabis and placebo phases of the trial (each of 3 weeks) by means of Symptom Checklist-90 Revised, Self-rating Anxiety Scale, Multiple Sclerosis Functional Composite (of which 1 dimension is the Paced Auditory Serial Additional Test that was used to evaluate cognition), Visual Analogue Scale on health-related quality of life, Multiple Sclerosis Impact Scale-29, and Fatigue Severity Scale. RESULTS: Postplacebo versus postcannabinoid scores showed that no significant differences could be detected on all the variables under study. A significant positive correlation was found between Delta-9-tetrahydrocannabinol blood levels and scores at the General Symptomatic Index and at the "interpersonal sensitivity," "aggressive behaviour," and "paranoiac tendencies" subscales of the Symptom Checklist-90 Revised. No serious adverse events, abuse tendencies, or direct withdrawal symptoms were reported. Increased desire for Sativex with secondary depression was reported in 1 subject. CONCLUSIONS: Cannabinoid treatment did not induce psychopathology and did not impair cognition in cannabis-naïve patients with MS. However, the positive correlation between blood levels of Delta-9-tetrahydrocannabinol and psychopathological scores suggests that at dosages higher than those used in therapeutic settings, interpersonal sensitivity, aggressiveness, and paranoiac features might arise, although greater statistical power would be necessary to confirm this finding.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
A Rating Instrument For Anxiety Disorders
Zung, W. W. K. (1971) · Psychosomatics · doi:10.1016/s0033-3182(71)71479-0 · Cited by 4,578
Lr, D., & Derogatis, L. R. (1983) · Medical Entomology and Zoology · Cited by 2,027
The Multiple Sclerosis Impact Scale (MSIS-29): A new patient-based outcome measure
Hobart, J. (2001) · Brain · doi:10.1093/brain/124.5.962 · Cited by 1,120
D'Souza, D. C., Perry, E., MacDougall, L., Ammerman, Y., Cooper, T., Wu, Y.-T., Braley, G., Gueorguieva, R., & Krystal, J. H. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300496 · Cited by 1,024 · cited 2×
“The acute administration of cannabis was reported to produce transient effects on several neuropsychological functions (eg, attention, memory, visual-motor coordination, verbal fluency, and psychomotor speed).(3,9,10) In Bheavy users[ (eg, subjects smoking several joints per day, during periods of many years), a long-…”
BackgroundResultFischer, J. S., Rudick, R. A., Cutter, G. R., Reingold, S. C., & National MS Society Clinical Outcomes Assessment Task Force (1999) · Multiple Sclerosis Journal · doi:10.1177/135245859900500409 · Cited by 993
Cognitive Functioning of Long-term Heavy Cannabis Users Seeking Treatment
Solowij, N. (2002) · JAMA · doi:10.1001/jama.287.9.1123 · Cited by 798
Henquet, C., Krabbendam, L., Spauwen, J., Kaplan, C., Lieb, R., Wittchen, H.-U., & van Os, J. (2005) · BMJ · doi:10.1136/bmj.38267.664086.63 · Cited by 765
Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis
Rog, D. J., Nurmikko, T. J., Friede, T., & Young, C. A. (2005) · Neurology · doi:10.1212/01.wnl.0000176753.45410.8b · Cited by 679 · cited 1×
“Although a previous study reported an improvement on PASAT performances during a period of 2 weeks,(27) our results are in accordance with a 4-week study, which did not find any difference compared with placebo.(28) Our findings support the hypothesis that cannabinoids taken as a treatment for MS symptoms do not affec…”
ResultSvendsen, K. B., Jensen, T. S., & Bach, F. W. (2004) · BMJ · doi:10.1136/bmj.38149.566979.ae · Cited by 500
Research works printed but not linked: 1
- Rog, 2005, Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis., Neurology, 65, 812, 10.1212/01.wnl.0000176753.45410.8b · DOI · Paper page
Cited by
Black, N., Stockings, E., Campbell, G., Tran, L. T., Zagic, D., Hall, W. D., Farrell, M., & Degenhardt, L. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30401-8 · Cited by 564
Hill, K. P. (2015) · JAMA · doi:10.1001/jama.2015.6199 · Cited by 508
Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options
Garakani, A., Murrough, J. W., Freire, R. C., Thom, R. P., Larkin, K., Buono, F. D., & Iosifescu, D. V. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.595584 · Cited by 440
“In one of those studies (240), THC-CBD was effective in the treatment of pain and sleep disturbances, while in the second study (241) THC-CBD was not effective for pain.”
BackgroundResultBoggs, D. L., Nguyen, J. D., Morgenson, D., Taffe, M. A., & Ranganathan, M. (2018) · Neuropsychopharmacology · doi:10.1038/npp.2017.209 · Cited by 238
“In a placebo-controlled crossover study (Aragona et al, 2009) of 17 individuals, MS patients were evaluated after nabiximols administration.”
BackgroundSmoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial
Corey-Bloom, J., Wolfson, T., Gamst, A., Jin, S., Marcotte, T. D., Bentley, H., & Gouaux, B. (2012) · Canadian Medical Association Journal · doi:10.1503/cmaj.110837 · Cited by 235
“Previous studies that have used different de livery systems (pills, oral mucosal sprays) and evaluated participants at study completion rather than within one hour of smoking have reported no or limited adverse effects on cognition.(11,18,22,23) However, smoked cannabis was associated with acute cognitive effects amon…”
Result
Metadata
- Authors
- Aragona, M., Onesti, E., Tomassini, V., Conte, A., Gupta, S., Gilio, F., Pantano, P., Pozzilli, C., & Inghilleri, M.
- Affiliations
- Sapienza University of Rome (IT)
- Westchester Medical Center (US)
- Corresponding author
- Aragona, Massimiliano
- ORCID
- Venue
- Clinical Neuropharmacology
- Published
- 2009-01
- Volume
- 32
- Issue
- 1
- Pages
- 41-47
- ISSN
- 0362-5664 (ISSN-L)
- OpenAlex
- W2036272035
- Cited by
- 109
- References
- 45
- Citations by year
- 2026: 6 · 2025: 2 · 2024: 4 · 2023: 6 · 2022: 16 · 2021: 4 · 2020: 9 · 2019: 3 · 2018: 5 · 2017: 5 · 2016: 3 · 2015: 8 · 2014: 6 · 2013: 6 · 2012: 9
- FWCI
- 3.97
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Neuropharmacology (publishedVersion)
- PubMed (publishedVersion)
- ORCA Online Research @Cardiff (Cardiff University) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Funders
- GW Pharmaceuticals
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Keywords
- multiple sclerosis, Sativex, psychopathology, cognitive impairment, delta-9-tetrahydrocannabinol, abuse liability, quality of life, fatigue, motor function, adverse effects, interpersonal sensitivity, aggression, paranoia
- MeSH terms
- Adult, Cannabidiol, Cannabinoids, Cognition Disorders, Disability Evaluation, Double-Blind Method, Female, Humans, Male, Middle Aged, Multiple Sclerosis, Neuropsychological Tests, Psychiatric Status Rating Scales, Statistics as Topic, Dronabinol, Treatment Outcome, Cross-Over Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Psychopathological and Cognitive Effects of Therapeutic Cannabinoids in Multiple Sclerosis: A Double-Blind, Placebo Controlled, Crossover Study. https://app.cochat.ai/papers/10.1097/wnf.0b013e3181633497
- The paper
- Aragona, M., Onesti, E., Tomassini, V., Conte, A., Gupta, S., Gilio, F., Pantano, P., Pozzilli, C., & Inghilleri, M. (2009). Psychopathological and Cognitive Effects of Therapeutic Cannabinoids in Multiple Sclerosis: A Double-Blind, Placebo Controlled, Crossover Study. Clinical Neuropharmacology. https://doi.org/10.1097/wnf.0b013e3181633497
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.